CN115517369A - Composite protein polypeptide powder for protecting cardiovascular and cerebrovascular and improving immunity and preparation method thereof - Google Patents
Composite protein polypeptide powder for protecting cardiovascular and cerebrovascular and improving immunity and preparation method thereof Download PDFInfo
- Publication number
- CN115517369A CN115517369A CN202211179671.XA CN202211179671A CN115517369A CN 115517369 A CN115517369 A CN 115517369A CN 202211179671 A CN202211179671 A CN 202211179671A CN 115517369 A CN115517369 A CN 115517369A
- Authority
- CN
- China
- Prior art keywords
- powder
- oligopeptide
- peptide
- protein polypeptide
- improving immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 112
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 95
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 37
- 230000036039 immunity Effects 0.000 title claims abstract description 35
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 28
- 239000002131 composite material Substances 0.000 title claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000002526 effect on cardiovascular system Effects 0.000 title claims description 16
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 65
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 65
- 244000269722 Thea sinensis Species 0.000 claims abstract description 31
- 241000209140 Triticum Species 0.000 claims abstract description 27
- 235000021307 Triticum Nutrition 0.000 claims abstract description 27
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 26
- 235000020279 black tea Nutrition 0.000 claims abstract description 26
- 241000251511 Holothuroidea Species 0.000 claims abstract description 25
- 229920001202 Inulin Polymers 0.000 claims abstract description 23
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 23
- 229920002472 Starch Polymers 0.000 claims abstract description 23
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 23
- 229940029339 inulin Drugs 0.000 claims abstract description 23
- 235000009566 rice Nutrition 0.000 claims abstract description 23
- 235000019698 starch Nutrition 0.000 claims abstract description 23
- 239000008107 starch Substances 0.000 claims abstract description 23
- 244000068988 Glycine max Species 0.000 claims abstract description 22
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 22
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 22
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940013618 stevioside Drugs 0.000 claims abstract description 22
- 235000019202 steviosides Nutrition 0.000 claims abstract description 22
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 19
- 240000008042 Zea mays Species 0.000 claims abstract description 19
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 19
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 19
- 235000005822 corn Nutrition 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000010447 xylitol Nutrition 0.000 claims abstract description 19
- 239000000811 xylitol Substances 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 19
- 229960002675 xylitol Drugs 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 240000007594 Oryza sativa Species 0.000 claims abstract 7
- 238000003756 stirring Methods 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000005303 weighing Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 239000011812 mixed powder Substances 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 20
- 239000000126 substance Substances 0.000 abstract description 17
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 230000036772 blood pressure Effects 0.000 abstract description 11
- 230000009084 cardiovascular function Effects 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 235000013406 prebiotics Nutrition 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 25
- 230000001276 controlling effect Effects 0.000 description 24
- 241000209094 Oryza Species 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 7
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 7
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000008455 cerebrovascular function Effects 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 4
- 229940107187 fructooligosaccharide Drugs 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composite protein polypeptide powder for protecting cardiovascular function and improving immunity and a preparation method thereof, and the composite protein polypeptide powder comprises the following raw materials: soybean peptide powder, wheat oligopeptide, corn oligopeptide powder, rice oligopeptide powder, hydrolyzed collagen, black tea powder, inulin, sea cucumber peptide, xylitol, water-soluble starch and stevioside. The invention mixes soybean peptide powder with wheat oligopeptide, corn oligopeptide powder, rice oligopeptide powder, sea cucumber peptide, hydrolyzed collagen and black tea powder according to the optimal proportion, can obviously reflect the characteristic that the short peptide is quickly absorbed by human body, strengthens the supplement and utilization of the organism, and is matched with prebiotics substances such as inulin, xylitol, water-soluble starch and the like, so that the beneficial flora in the intestinal tract of the human body can be improved, the absorption of protein and composite short peptide substances is enhanced, and the ideal effects of reducing blood pressure, cholesterol, blood fat, oxidation resistance, fatigue resistance, immunity enhancement and the like can be achieved.
Description
Technical Field
The invention belongs to the field of nutritional food, and particularly relates to composite protein polypeptide powder for protecting heart and cerebral vessels and improving immunity and a preparation method thereof.
Background
Patients with cardiovascular and cerebrovascular diseases in old people often feel fatigue and lack of strength, and the immunity is low, so that the population proportion of the old people is large and reaches more than 3 hundred million according to statistics. After the age of 45 years, muscular tissues begin to atrophy, and the basic metabolism of the muscle becomes slow and weak with the decrease of daily exercise, so that the demand of food is reduced, but the human body still needs a basic amount of nutrients. The protein is the most important raw material for human body growth, development, renewal and repair of tissue cells, is the basis for life maintenance, can form various enzymes, hormones and antibodies, participate in substance metabolism and regulation of physiological functions, improve immunity, and is a substance condition for protecting the body from being damaged. Systemic proteins account for about 20% of body weight and are essential elements of the human body.
Proteins required by the body, from food sources, there are two main routes: the animal protein is complete in species, sufficient in quantity and proper in proportion. The amino acid contained in the product is close to the requirement of human body, so the product has high nutritive value. Another vegetarian species is an incomplete or semi-complete protein that contains insufficient amounts of amino acids and lacks certain essential amino acids.
The elderly need to supply enough protein, which accounts for about 15% of the total calories, 1.0-1.5 g per kg of body weight per day. The elderly have reduced digestion and absorption functions, reduced detoxifying function of liver, and reduced ability of kidney to remove waste. If excessive protein intake causes dyspepsia and increased burden on liver and kidney, it will also cause adverse effects and damage health. Whether the protein intake is sufficient and appropriate depends mainly on the amounts and mutual ratios of various amino acids absorbed and utilized after the protein is digested, whether the physiological needs of the organism can be met, and whether the needs of various amino acids, particularly the needs of 'essential amino acids' can be sufficiently supplied.
Peptides belong to a class of substances formed by the association of amino acids. The human body needs to supplement peptide, and generally only needs to eat food rich in protein. Since proteins are absorbed and digested in the human body and metabolized into amino acids, the amino acids are synthesized into peptides through a series of steps. The peptide has the functions of detoxifying, maintaining the immune system function of the body and the like, is an essential substance for the body to complete various complex activities, and has multiple physiological activities including antioxidation, blood pressure reduction, cholesterol reduction, blood fat reduction and fatigue resistance according to literature research. However, some people including the elderly directly cause the shortage of short peptide substances due to the insufficient protein supplement, thereby causing the normal functions of the body, the damaged cardiovascular and cerebrovascular functions and the low immunity. Therefore, short peptide substances need to be reasonably supplemented from the outside, active short peptide substances need to be supplemented to human bodies, the physiological needs of human bodies are met, the cardiovascular and cerebrovascular functions are improved and protected, and the immunity is improved. The healthy intestinal tract is a good guarantee for the body to absorb nutrient substances, and if the intestinal tract has symptoms, even if short peptide substances are supplemented to the body, the short peptide substances cannot be absorbed completely, so that the short peptide substances are not absorbed sufficiently, and the corresponding effect cannot be achieved. There is a need for a nutritional food which can enhance the absorption of proteins and composite short peptides, and achieve the effects of lowering blood pressure, reducing cholesterol, reducing blood lipid, resisting oxidation, resisting fatigue, enhancing immunity, etc.
Disclosure of Invention
The invention aims to provide composite protein polypeptide powder for protecting heart and cerebral vessels and improving immunity and a preparation method thereof.
In order to achieve the purpose, the invention provides the following technical scheme that the composite protein polypeptide powder for protecting cardiovascular functions and improving immunity comprises the following raw materials: soybean peptide powder, wheat oligopeptide, corn oligopeptide powder, rice oligopeptide powder, hydrolyzed collagen, black tea powder, inulin, sea cucumber peptide, xylitol, water-soluble starch and stevioside.
Preferably, the composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity comprises the following raw materials in percentage by weight: 8-38% of soybean peptide powder, 0.08-1.5% of wheat oligopeptide, 0.08-1.4% of corn oligopeptide powder, 0.07-1.5% of rice oligopeptide powder, 0.08-1.0% of hydrolyzed collagen, 1-15% of black tea powder, 15-35% of inulin, 0.08-1.2% of sea cucumber peptide, 8-30% of xylitol, 8-30% of water-soluble starch and 0.08-0.6% of stevioside.
Preferably, the composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity comprises the following raw materials in percentage by weight: 10-30% of soybean peptide powder, 0.1-1% of wheat oligopeptide, 0.1-1.2% of corn oligopeptide powder, 0.1-1.5% of rice oligopeptide powder, 0.1-0.8% of hydrolyzed collagen, 2-10% of black tea powder, 20-30% of inulin, 0.1-0.8% of sea cucumber peptide, 10-25% of xylitol, 10-26% of water-soluble starch and 0.1-0.5% of stevioside.
Preferably, the composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity comprises the following raw materials in percentage by weight: 20% of soybean peptide powder, 0.4% of wheat oligopeptide, 0.4% of corn oligopeptide powder, 0.4% of rice oligopeptide powder, 0.2% of hydrolyzed collagen, 5% of black tea powder, 26% of inulin, 0.1% of sea cucumber peptide, 22% of xylitol, 25.48% of water-soluble starch and 0.2% of stevioside.
The invention also provides a preparation method of the composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity, which comprises the following steps:
step 1, weighing soybean peptide powder, wheat oligopeptide, corn oligopeptide powder, rice oligopeptide powder and hydrolyzed collagen according to weight percentage, controlling the rotating speed of a three-dimensional mixer to be 7 revolutions per minute, stirring for 40 minutes to obtain uniform base powder, and weighing stevioside for later use;
step 2, weighing black tea powder, inulin, sea cucumber peptide, xylitol and water-soluble starch according to the weight percentage, adding the black tea powder, the inulin, the sea cucumber peptide, the xylitol and the water-soluble starch into a three-dimensional mixer, controlling the rotating speed at 10 revolutions per minute, and stirring for 40 minutes to obtain uniformly mixed powder;
step 3, adding the base powder obtained in the step 1 into the mixed powder obtained in the step 2, putting the mixture into a three-dimensional mixer, controlling the rotating speed at 8 revolutions per minute, stirring for 35 minutes, uniformly stirring, and taking out for later use;
and 4, adding the mixture obtained in the step 3 into a wet granulator, dissolving the stevioside for later use by using a small amount of 85% ethanol, adding 95% ethanol to prepare a binder, adding the binder into the granulator at a constant speed, and granulating for 15 minutes at normal temperature to obtain a soft material.
And 5, putting the soft material into a hot air circulation oven by using a stainless steel plate, controlling the temperature to be 60-70 ℃, controlling the drying time to be 2-3 hours, and controlling the moisture of the dried material to be below 3.5 percent.
And 6, subpackaging and packaging the dried materials into boxes to prepare finished products.
Principle of action
The soybean peptide is composed of 2-6 amino acids, has a molecular weight of 200-800Dalton, has the effects of improving lipid metabolism, preventing arteriosclerosis, enhancing physical performance of a human body, promoting muscle red cell recovery, eliminating fatigue, promoting absorption of calcium, phosphorus and other trace elements, can form soybean peptide complex calcium to directly enter blood to be deposited in bones, does not need participation of vitamin D, achieves the effect of improving the strength of bones, has the effects of enhancing the activity of phagocytes and B cells, enhancing the immune function, resisting cancer and aging, protecting epidermal cells, preventing melanin pigmentation, eliminating oxidative free radicals and playing a role in blood clearance. Inhibiting Angiotensin Converting Enzyme (ACE) activity, preventing vascular smooth muscle contraction, and lowering blood pressure. It is worth mentioning that the blood pressure lowering effect is only for the patients with hypertension, but not for normal people.
The composite protein polypeptide powder is prepared by reasonably preparing corn oligopeptide powder, rice oligopeptide powder, hydrolyzed collagen, sea cucumber peptide and black tea powder by using soybean peptide, so as to fully exert the physiological activity of the short peptide, protect the cardiovascular and cerebrovascular functions and improve the immunity.
The wheat oligopeptide has effect of inhibiting cholesterol increase. The wheat oligopeptide can promote insulin secretion, and the functional substance is oligomethionine, and can be used for regulating blood sugar of human and improving diabetes symptoms. The wheat peptide can block the action of angiotensin enzyme, thereby having the effect of lowering blood pressure. One of the characteristics of the wheat oligopeptide is that the wheat oligopeptide contains homoglutamine, can effectively regulate nerves and can be used as a special nutrient substance in the case of intestinal dysfunction. The wheat oligopeptide has multiple biological activities of ACE (angiotensin converting enzyme) inhibition, immunoregulation, oxidation resistance and the like, and can stimulate lymphocyte proliferation of an organism, enhance phagocytic function of macrophages, improve the capability of the organism of resisting infection of external pathogens, reduce the morbidity of the organism and the like.
The wheat oligopeptide is a wheat proteolysis product, can inhibit the activity of angiotensin converting enzyme, and can prevent angiotensinogen from being converted into angiotensin II which can increase blood pressure, thereby physiologically reducing blood pressure and having no effect on normal blood pressure.
The corn oligopeptide contains various bioactive substances, so that the effect of reducing the content of triglyceride and cholesterol in blood can be achieved, the condition that the blood is viscous can be avoided, the blood circulation can be promoted to be smoother, angiotensin can be converted into hydrolase, the effects of reducing blood pressure and blood fat and the like can be achieved, and hyperlipidemia and hypertension can be avoided.
The rice oligopeptide can inhibit the activity of Angiotensin Converting Enzyme (ACE), prevent the contraction of vascular endings, achieve the effect of reducing blood pressure and has obvious curative effect on patients with cardiovascular diseases. The research shows that the rice peptide has the capability of immunoregulation activity, can enhance the phagocytic capability of phagocytic cells, and achieves the effect of improving the immunity of human bodies by enhancing the capabilities of the rice peptide in clearing waste cells in human bodies and improving metabolic waste and harmful viruses.
The sea cucumber peptide can promote cellular immunity and humoral immunity functions, and enhance the activity of mononuclear macrophages and NK cells, and shows that the sea cucumber peptide has the function of enhancing immunity. The antioxidant effect can generate a small amount of oxygen-containing free radicals in the normal physiological metabolic process of a human body, the excessive free radicals can attack biological macromolecules such as protein, lipid, DNA and the like, damage cell structures, interfere the normal metabolic activity of the human body, cause diseases such as cancer, senile dementia, arteriosclerosis, arthritis and the like, and accelerate the aging process of the human body. Experiments prove that the sea cucumber polypeptide has certain scavenging capacity for oxygen-containing free radicals.
Collagen is the main component of connective tissue, and hydrolyzed collagen in the connective tissue is often interwoven with polysaccharide protein to form a net structure, so that a certain mechanical strength is generated, and the collagen is a material basis for supporting a human body curve and reflecting a stiff and straight posture.
The black tea powder contains a large amount of polyphenols, and has effects of resisting arteriosclerosis, thereby reducing arteriosclerosis incidence. According to the research of the French clinical education chief Ai Mier, luo Zhi doctors, the content of triglyceride and cholesterol can be reduced by drinking the Tuo tea. Of the 13 cases, 10 significantly reduced the triglyceride content in humans; there were 11 of the 16 cases with a cholesterol drop, with the best effect accounting for 12.5% of all cases.
The data report that 80 patients with hypertension were tested clinically, and 32 patients had a return of their arterial blood pressure to normal and a decrease in blood cholesterol within 5 days after treatment with tea.
It was also found that people who had a history of drinking tea for 14 years had lower arteriosclerosis than the control group drinking coffee under the same conditions. According to the observation of scanburg, people who like drinking Chinese tea suffer from arteriosclerosis less frequently. Tea polyphenol in tea has strong effect of decomposing fat, thereby reducing the content of triglyceride and cholesterol in human body.
The prebiotics provide food for the probiotics, and can be decomposed and absorbed by the beneficial bacteria in the intestinal tract to promote the growth and reproduction of the beneficial bacteria. Prebiotics enter the gastrointestinal tract in an undigested form and indirectly promote gastrointestinal health and nutrient absorption by lowering the pH to promote the growth of beneficial bacteria such as bifidobacteria. Can improve intestinal flora composition. Promoting the health of the host, inducing systemic immunity in intestinal cavity and improving the constitution of the host.
The probiotics can construct the first stage of immunity of a human body, the probiotics are adhered to the surface of the intestinal mucosa to form a biofilm barrier, a large number of probiotics occupy pathogenic bacteria, and competitively colonize the surface of the intestinal mucosa, so that harmful bacteria lose the foundation of the ground and cannot survive. The intestinal tract innate immune cells can be promoted to mature and reproduce, a large number of immune innate cells exist in intestinal tract mucous membranes, the intestinal tract innate cells can mature and reproduce under the stimulation of probiotics, and the intestinal tract innate cells are differentiated into different organs and tissues of a body and need to mature immune cells, such as liver kupffer cells, brain glial cells and skin langerhans cells, so that the intestinal tract innate immune cells play a role in immunity and disease resistance. The probiotics can ensure the reproduction of beneficial bacteria in the intestinal tract and promote the health of the intestinal tract.
Advantageous effects
The invention mixes soybean peptide powder, wheat oligopeptide, corn oligopeptide, rice oligopeptide, sea cucumber peptide, hydrolyzed collagen and black tea powder according to the optimal proportion, can obviously reflect the characteristic that the short peptide is quickly absorbed by human body, strengthens the supplement and utilization of the organism, and is matched with prebiotics substances such as inulin, xylitol, water-soluble starch and the like, so that the beneficial flora in the intestinal tract of the human body can be improved, the absorption of protein and composite short peptide substances is enhanced, and the ideal effects of reducing blood pressure, cholesterol, blood fat, oxidation, fatigue, immunity and the like can be achieved.
Detailed Description
The present invention will be specifically described below with reference to examples.
Example 1
A preparation method of composite protein polypeptide powder for protecting cardiovascular and cerebrovascular functions and improving immunity comprises the following specific preparation steps:
preparing materials: 20000 g of soybean peptide powder, 400 g of wheat oligopeptide, 400 g of corn oligopeptide powder, 400 g of rice oligopeptide powder, 200 g of hydrolyzed collagen, 5000 g of black tea powder, 26000 g of inulin, 100 g of sea cucumber peptide, 22000 g of xylitol, 25480 g of water-soluble starch and 20 g of stevioside.
Step 1, weighing soybean peptide powder, wheat oligopeptide, corn oligopeptide powder, rice oligopeptide powder and hydrolyzed collagen according to weight percentage, controlling the rotating speed of a three-dimensional mixer to be 7 revolutions per minute, stirring for 40 minutes to obtain uniform base powder, and weighing stevioside for later use;
step 2, weighing black tea powder, inulin, sea cucumber peptide, xylitol and water-soluble starch according to the weight percentage, adding the black tea powder, the inulin, the sea cucumber peptide, the xylitol and the water-soluble starch into a three-dimensional mixer, controlling the rotating speed at 10 revolutions per minute, and stirring for 40 minutes to obtain uniformly mixed powder;
step 3, adding the base powder obtained in the step 1 into the mixed powder obtained in the step 2, putting the mixture into a three-dimensional mixer, controlling the rotating speed at 8 revolutions per minute, stirring for 35 minutes, uniformly stirring, and taking out for later use;
and 4, adding the mixture obtained in the step 3 into a wet granulator, dissolving the reserved stevioside with a small amount of 85% ethanol, adding 95% ethanol to prepare a binder, adding the binder into the granulator at a constant speed, and granulating for 15 minutes at normal temperature to obtain a soft material.
And 5, putting the soft material into a hot air circulation oven by using a stainless steel plate, controlling the temperature to be 60-70 ℃, controlling the drying time to be 2-3 hours, and controlling the moisture of the dried material to be below 3.5 percent.
And 6, subpackaging the dried materials, namely 5 g of the dried materials in each bag, and packaging the dried materials into boxes, namely 15 bags in each box to obtain a finished product.
Example 2
A preparation method of composite protein polypeptide powder for protecting cardiovascular and cerebrovascular functions and improving immunity comprises the following specific preparation steps:
preparing materials: 40000 g of soybean peptide powder, 800 g of wheat oligopeptide, 800 g of corn oligopeptide powder, 800 g of rice oligopeptide powder, 400 g of hydrolyzed collagen, 10000 g of black tea powder, 52000 g of inulin, 200 g of sea cucumber peptide, 44000 g of xylitol, 50960 g of water-soluble starch and 40 g of stevioside.
Step 1, weighing soybean peptide powder, wheat oligopeptide, rice oligopeptide, sea cucumber peptide, casein peptide and albumin peptide according to weight percentage, controlling the rotating speed of a three-dimensional mixer to be 8 revolutions per minute, and stirring for 35 minutes to obtain uniform base powder;
step 2, weighing inulin, fructo-oligosaccharide, black tea powder, water-soluble starch, vitamin C and stevioside according to the weight percentage, adding the inulin, the fructo-oligosaccharide, the black tea powder, the water-soluble starch, the vitamin C and the stevioside into a three-dimensional mixer, controlling the rotating speed at 14 revolutions per minute, and stirring for 40 minutes to obtain uniformly mixed powder;
step 3, adding the base powder obtained in the step 1 into the mixed powder obtained in the step 2, controlling the rotating speed of a three-dimensional mixer to be 8 revolutions per minute, stirring for 35 minutes, uniformly stirring, and taking out for later use;
and 4, adding the mixture obtained in the step 3 into a wet granulator, adding a pure ethanol adhesive at a constant speed, and granulating at normal temperature for 15 minutes to obtain a soft material.
And 5, putting the soft material into a vacuum low-temperature dryer by using a stainless steel disc, controlling the vacuum degree to be-0.08 to-0.1 MPa, controlling the temperature to be 45-60 ℃, drying for 2-4 hours at a low temperature, and controlling the moisture of the dried material to be below 3.0 percent.
And 6, subpackaging the dried materials, namely 5 g of the dried materials in each bag, and packaging the dried materials into boxes, namely 30 bags in each box to obtain a finished product.
Example 3
A preparation method of composite protein polypeptide powder for protecting cardiovascular and cerebrovascular functions and improving immunity comprises the following specific preparation steps:
preparing materials: 60000 g of soybean peptide powder, 1200 g of wheat oligopeptide, 1200 g of corn oligopeptide powder, 1200 g of rice oligopeptide powder, 600 g of hydrolyzed collagen, 15000 g of black tea powder, 78000 g of inulin, 300 g of sea cucumber peptide, 66000 g of xylitol, 76440 g of water-soluble starch and 60 g of stevioside.
Step 1, weighing soybean peptide powder, wheat oligopeptide, rice oligopeptide, sea cucumber peptide, casein peptide and albumin peptide according to weight percentage, controlling the rotating speed of a three-dimensional mixer to be 8 revolutions per minute, and stirring for 35 minutes to obtain uniform base powder;
step 2, weighing inulin, fructo-oligosaccharide, black tea powder, water-soluble starch, vitamin C and stevioside according to the weight percentage, adding the inulin, the fructo-oligosaccharide, the black tea powder, the water-soluble starch, the vitamin C and the stevioside into a three-dimensional mixer, controlling the rotating speed at 14 revolutions per minute, and stirring for 40 minutes to obtain uniformly mixed powder;
step 3, adding the base powder obtained in the step 1 into the mixed powder obtained in the step 2, controlling the rotating speed of a three-dimensional mixer to be 8 revolutions per minute, stirring for 35 minutes, uniformly stirring, and taking out for later use;
and 4, adding the mixture obtained in the step 3 into a wet granulator, adding a pure ethanol adhesive at a constant speed, and granulating at normal temperature for 15 minutes to obtain a soft material.
And 5, putting the soft material into a vacuum low-temperature dryer by using a stainless steel disc, controlling the vacuum degree to be-0.08 to-0.1 MPa, controlling the temperature to be 45-60 ℃, drying for 2-4 hours at a low temperature, and controlling the moisture of the dried material to be below 3.0 percent.
And 6, subpackaging the dried materials, namely 5 g of the dried materials in each bag, and packaging the dried materials into boxes, namely 30 bags in each box to obtain a finished product.
The composite protein polypeptide powder prepared by the method for protecting cardiovascular and cerebrovascular functions and improving immunity has fine and rich taste, has the unique taste of peptide and black tea, is slightly bitter but not sweet, and is particularly suitable for middle-aged and elderly people and patients with cardiovascular and cerebrovascular diseases.
Claims (8)
1. The composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity is characterized by comprising the following raw materials: soybean peptide powder, wheat oligopeptide, corn oligopeptide powder, rice oligopeptide powder, hydrolyzed collagen, black tea powder, inulin, sea cucumber peptide, xylitol, water-soluble starch and stevioside.
2. The composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity and the preparation method thereof according to claim 1, wherein the raw materials comprise, by weight: 8-38% of soybean peptide powder, 0.08-1.5% of wheat oligopeptide, 0.08-1.4% of corn oligopeptide powder, 0.07-1.5% of rice oligopeptide powder, 0.08-1.0% of hydrolyzed collagen, 1-15% of black tea powder, 15-35% of inulin, 0.08-1.2% of sea cucumber peptide, 8-30% of xylitol, 8-30% of water-soluble starch and 0.08-0.6% of stevioside.
3. The composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity and the preparation method thereof according to claim 2, wherein the raw materials comprise, by weight: 10-30% of soybean peptide powder, 0.1-1% of wheat oligopeptide, 0.1-1.2% of corn oligopeptide powder, 0.1-1.5% of rice oligopeptide powder, 0.1-0.8% of hydrolyzed collagen, 2-10% of black tea powder, 1.5-5% of inulin, 0.1-0.8% of sea cucumber peptide, 10-25% of xylitol, 10-25% of water-soluble starch and 0.1-0.5% of stevioside.
4. The composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity and the preparation method thereof according to claim 3, wherein the raw materials comprise, by weight: 20% of soybean peptide powder, 0.4% of wheat oligopeptide, 0.4% of corn oligopeptide powder, 0.4% of rice oligopeptide powder, 0.2% of hydrolyzed collagen, 5% of black tea powder, 26% of inulin, 0.1% of sea cucumber peptide, 22% of xylitol, 25.48% of water-soluble starch and 0.2% of stevioside.
5. The preparation method of the composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity according to claim 1, which comprises the following steps:
step 1, weighing soybean peptide powder, wheat oligopeptide, corn oligopeptide powder, rice oligopeptide powder and hydrolyzed collagen according to weight percentage, putting the mixture into a three-dimensional mixer, stirring to obtain uniform base powder, and weighing stevioside for later use;
weighing black tea powder, inulin, sea cucumber peptide, xylitol and water-soluble starch according to the weight percentage, adding the materials into a three-dimensional mixer, and stirring to obtain uniformly mixed powder;
step 3, adding the base powder obtained in the step 1 into the mixed powder obtained in the step 2, putting the mixture into a three-dimensional mixer, stirring the mixture uniformly, and taking the mixture out for later use;
and 4, adding the mixture obtained in the step 3 into a wet granulator, dissolving the reserved stevioside with a small amount of 85% ethanol, adding 95% ethanol to prepare a binder, adding the binder into the granulator at a constant speed, and granulating for 15 minutes at normal temperature to obtain a soft material.
And 5, putting the soft material into a hot air circulation oven by using a stainless steel plate, controlling the temperature to be 60-70 ℃, controlling the drying time to be 2-3 hours, and controlling the moisture of the dried material to be below 3.5 percent.
And step 6, subpackaging and packaging the dried materials into boxes to prepare finished products.
6. The method for preparing the composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity according to claim 5, wherein in the step 1, the rotation speed is controlled to be 7 revolutions per minute, and the stirring is carried out for 40 minutes.
7. The method for preparing the composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity according to claim 5, wherein in the step 2, the rotation speed is controlled at 10 revolutions per minute, and the stirring is carried out for 40 minutes.
8. The method for preparing the composite protein polypeptide powder for protecting cardiovascular and cerebrovascular vessels and improving immunity according to claim 5, wherein in the step 3, the rotation speed is controlled to be 8 revolutions per minute, and the stirring is carried out for 35 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211179671.XA CN115517369A (en) | 2022-09-27 | 2022-09-27 | Composite protein polypeptide powder for protecting cardiovascular and cerebrovascular and improving immunity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211179671.XA CN115517369A (en) | 2022-09-27 | 2022-09-27 | Composite protein polypeptide powder for protecting cardiovascular and cerebrovascular and improving immunity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115517369A true CN115517369A (en) | 2022-12-27 |
Family
ID=84699532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211179671.XA Pending CN115517369A (en) | 2022-09-27 | 2022-09-27 | Composite protein polypeptide powder for protecting cardiovascular and cerebrovascular and improving immunity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115517369A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114009789A (en) * | 2021-11-03 | 2022-02-08 | 刘严峰 | Food for improving cardiovascular and cerebrovascular diseases and preparation process thereof |
| CN114098089A (en) * | 2021-10-22 | 2022-03-01 | 朗姿赛尔生物科技（广州）有限公司 | Composite peptide composition and composite peptide seasoning tea |
| CN114376237A (en) * | 2020-10-21 | 2022-04-22 | 山西振东五和健康科技股份有限公司 | Sea cucumber peptide composite powder and preparation method thereof |
| CN114403454A (en) * | 2022-01-05 | 2022-04-29 | 陕西恒晟远誉生物医药科技有限公司 | Composite protein polypeptide calcium powder |
-
2022
- 2022-09-27 CN CN202211179671.XA patent/CN115517369A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114376237A (en) * | 2020-10-21 | 2022-04-22 | 山西振东五和健康科技股份有限公司 | Sea cucumber peptide composite powder and preparation method thereof |
| CN114098089A (en) * | 2021-10-22 | 2022-03-01 | 朗姿赛尔生物科技（广州）有限公司 | Composite peptide composition and composite peptide seasoning tea |
| CN114009789A (en) * | 2021-11-03 | 2022-02-08 | 刘严峰 | Food for improving cardiovascular and cerebrovascular diseases and preparation process thereof |
| CN114403454A (en) * | 2022-01-05 | 2022-04-29 | 陕西恒晟远誉生物医药科技有限公司 | Composite protein polypeptide calcium powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106798252B (en) | Natto product with effects of regulating intestines and stomach, reducing blood fat and dissolving thrombus | |
| CN108294318A (en) | It is a kind of weight-reducing and control body weight functional food | |
| CN108703249A (en) | A kind of collagen product and preparation method thereof | |
| CN106578801A (en) | Comprehensive enzyme powder with hypoglycemic effect and preparation method thereof | |
| CN101785547A (en) | Natto nanometer calcium chewable tablets | |
| CN103766904A (en) | Preparation of capsule with function of lowering lipid and facilitating feces excretion and application of capsule | |
| JP4132635B2 (en) | Uninactivated enzyme-enhanced composition | |
| CN111972659A (en) | Meal replacement powder for chia seed Chinese yam | |
| CN108260790A (en) | A kind of nourishing albumen powder and preparation method thereof | |
| CN102776102B (en) | Health wine containing bee products | |
| CN1943695A (en) | A tortoise preparation and its production technology | |
| CN115969961A (en) | Calcium, VD and protein peptide composition for improving bone mineral density and preparation method and application thereof | |
| CN115053929B (en) | Formula milk powder suitable for fatty liver people and preparation thereof | |
| CN103190677A (en) | Solid cereal beverage and preparation process thereof | |
| CN105497106A (en) | Traditional Chinese medicine compound fermentation powder and preparation method thereof | |
| CN110140879A (en) | A kind of coarse cereal powder and preparation method thereof rich in probiotics | |
| CN115517369A (en) | Composite protein polypeptide powder for protecting cardiovascular and cerebrovascular and improving immunity and preparation method thereof | |
| CN109497470A (en) | A kind of chlorella pyrenoidosa polypeptide alleviates getting fat composition and preparation method thereof | |
| CN102742654B (en) | Beautification probiotic ewe milk tablet and preparation method thereof | |
| CN114557447A (en) | Composite nutriment and preparation method thereof | |
| CN106072668A (en) | Health product of eliminating toxin and beautifying the skin and preparation method thereof | |
| CN112219903A (en) | Body-shaping and qi-tonifying milk powder for women and preparation method thereof | |
| CN111436618A (en) | Passion fruit polypeptide composition and preparation method thereof | |
| CN111772178A (en) | Noni grain germ enzyme and preparation method and application thereof | |
| CN110547463A (en) | chicory nitraria tangutorum bobr green wheat meal replacement powder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |